Skip to main content
OpenTrials
Completed

NCT Number: NCT06251440

Initial Experience of Transabdominal Fetal Reduction in Nepal

Multifetal pregnancies are common in in vitro fertilization. Multifetal gestation increases maternal and fetal morbidity and mortality. We perform fetal reduction in our hospital by intra-thoracic injection of potassium chloride. This manuscript is description of our initial experience.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

In Vitro Fertilization

Age range

18 year–45 year

Sex eligibility

Female

Study type

Observational

Primary location

Prajwal Dahal

Kathmandu, Bagmati, Nepal

About this study

Assisted reproductive technology and stimulated conception have led to an increase in the prevalence of high order multifetal pregnancies (MFPs) in recent times. MFPs are associated with high maternal and fetal complications. Fetal mortality and morbidity are due to complications of prematurity. Prevalence of pregnancy induced hypertension, pre-eclampsia, eclampsia, antepartum hemorrhage, post-partum hemorrhage, gestational diabetes and difficult deliveries are more in mother with MFP. Embryo/Fetal reduction in high order MFPs helps in prolongation of gestation. Multifetal pregnancy reduction (MFPR) is secondary prevention of the risks associated with MFP. Trans-abdominal intracardiac injection of KCl is a simple, safe and effective technique for MFPR. We are among the first few centers in Nepal doing MFPR. In this study, we are sharing our initial experience of the procedure.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • pregnant females with multifetal gestation who opt to undergo fetal reduction

Exclusion criteria

  • who do not give consent

Treatment and study plan

Fetal Reduction

Drug

Under ultrasound guidance, intracardiac injection of 0.2 to 3.0 ml of 15% weight/volume (2 miliequivalent/mililiter ) potassium chloride (KCl) was administered via transabdominal route

Other names: Selective fetal reduction

Primary outcomes

  1. Transabdominal ultrasonography guided fetal reduction is safe and effective in first trimester

    Time frame: 4.5 years

    To share initial experience of transabdominal multifetal pregnancy reduction (MFPR) in Nepal

Sponsors and collaborators

Lead sponsor

Grande International Hospital, Nepal

Other

Registry information

Official study title

Transabdominal Fetal Reduction in Higher Order Multiple Pregnancies - a Pioneer Study in Nepal

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
Feb 9, 2024
Registry last updated
Feb 9, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.